September 25, 2024

Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Supplemental Figure 2 shows bar graph of quantification of cells that have >25 gH2Ax foci per cell in M27 cell line, after treatment with peposertib and radiation

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Ji et al. (Wed,) studied this question.

synapsesocial.com/papers/68e5778bb6db6435875173f0 https://doi.org/https://doi.org/10.1158/1535-7163.27102352

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts2024
2Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts2024
3Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts2024
4Supplementary Figure 1 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts2024
5Supplementary Figure 1 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts2024

Preguntar a la IA

Me gusta

Guardar